Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed

SANGAMO THERAPEUTICS, INC

Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).
CFO Prathyusha Duraibabu's employment terminated effective Feb 2, 2026.
Nikunj Jain (VP Finance, Controller) appointed Interim CFO effective Feb 3, 2026; no additional compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.